AT

AGS Therapeutics

Biotechnology · Paris, Île-de-france, France · Founded 2020

About

AGS has shown MEVs to be a safe, targeted and highly versatile delivery system for mRNA, siRNA, DNA oligos, plasmids, proteins, and peptides relevant to a broad range of human diseases. AGS-M, a company’s CDMO subsidiary, produces the MEVs needed to support R&D and product development from AGS and from companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a two-billion-year-old single-cell algae, labelled by the FDA as GRAS for consumption as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with processes that are both eco-friendly and easily scalable. AGS technology platforms (including MEV technology plus payload design and discovery) are a steady source of candidate products. AGS's more advanced products include AGS-1010, a topical product for the treatment of wAMD, and AGS-2010, an oral product for the treatment of an IBD. Through strategic partnerships and a commitment to scientific excellence, the company aims to challenge the delivery landscape and improve the lives of patients across the globe. For more information, visit www.ags-tx.com and www.ags-m.com

Company details may include data from People Data Labs, licensed CC BY 4.0.